Bethany C. Prudner

Bethany C. Prudner

Auto-generated profile, based on publicly available information

Bethany C. Prudner

Division of Medical Oncology, Washington University in St. Louis, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2019 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
BPBethany C Prudner
Bethany C Prudner
TBTyler Ball
Tyler Ball
RRRicha Rathore
Richa Rathore
Angela HirbeAngela Hirbe
Angela Hirbe
One of the most common malignancies affecting adults with the neurofibromatosis type 1 (NF1) cancer predisposition syndrome is the malignant peripheral nerve sheath tumor (MPNST), a highly aggressive sarcoma that typically develops from benign plexiform neurofibromas. Approximately 8–13% of individuals with NF1 will develop MPNST during young adulthood. There are few therapeutic options, and the vast majority of people with these cancers will die within 5 years of diagnosis. Despite efforts to understand the pathogenesis of these aggressive tumors, the overall prognosis remains dismal. This manuscript will review the current understanding of the cellular and molecular progression of MPNST, diagnostic workup of patients with these tumors, current treatment paradigms, and investigational treatment options. Additionally, we highlight novel areas of preclinical research, which may lead to future clinical trials. In summary, MPNST remains a diagnostic and therapeutic challenge, and future work is needed to develop novel and rational combinational therapy for these tumors.

15 August 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BPBethany C. Prudner
Bethany C. Prudner
RRRicha Rathore
Richa Rathore
ARAnthony M. Robinson
Anthony M. Robinson
AGAbigail Godec
Abigail Godec
SCSamuel F. Chang
Samuel F. Chang
Brian Van TineBrian Van Tine
Brian Van Tine
Purpose: The response to acute and long-term arginine starvation results in a conditional adaptive metabolic reprogramming that can be harnessed for therapeutic opportunities in ASS1-negative tumors. Here, we investigate the underlying biology of priming ASS1− tumors with arginine deiminase (ADI-PEG20) before treatment with gemcitabine (GEM) and docetaxel (DTX) in sarcoma, pancreatic cancer, and melanoma cell lines. Experimental Design: ASS1− tumor cell lines were treated to create LTAT (long-term ADI treated) cell lines (ASS1+) and used for drug combination studies. Protein expression of ASS1, dCK, RRM2, E2F1, c-MYC, and hENT1 was measured. c-MYC activity was determined, live-cell immunofluorescent studies for hENT1, uptake assays of FITC-cytosine probe, and rescue studies with a c-MYC inhibitor were all determined in the presence or absence of the ADI-PEG20:GEM:DTX. Results: In examining modulations within the pyrimidine pathway, we identified that the addition of DTX to cells treated with ADI-PEG20 resulted in translocation of stabilized c-Myc to the nucleus. This resulted in an increase of hENT1 cell-surface expression and rendered the cells susceptible to GEM. In vivo studies demonstrate that the combination of ADI-PEG20:GEM:DTX was optimal for tumor growth inhibition, providing the preclinical mechanism and justification for the ongoing clinical trial of ADI-PEG20, GEM, and DTX in sarcoma. Conclusions: The priming of tumors with ADI-PEG20 and DTX results in the stabilization of c-MYC potentiating the effect of GEM treatment via an increase in hENT1 expression. This finding is applicable to ASS1-deficient cancers that are currently treated with GEM.

14 April 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CBCaitlyn B. Brashears
Caitlyn B. Brashears
BPBethany C. Prudner
Bethany C. Prudner
RRRicha Rathore
Richa Rathore
KCKatharine E. Caldwell
Katharine E. Caldwell
CDCarina A. Dehner
Carina A. Dehner
Brian Van TineBrian Van Tine
Brian Van Tine
Purpose: To investigate the metabolism of synovial sarcoma (SS) and elucidate the effect of malic enzyme 1 absence on SS redox homeostasis. Experimental Design: ME1 expression was measured in SS clinical samples, SS cell lines, and tumors from an SS mouse model. The effect of ME1 absence on glucose metabolism was evaluated utilizing Seahorse assays, metabolomics, and C13 tracings. The impact of ME1 absence on SS redox homeostasis was evaluated by metabolomics, cell death assays with inhibitors of antioxidant systems, and measurements of intracellular reactive oxygen species (ROS). The susceptibility of ME1-null SS to ferroptosis induction was interrogated in vitro and in vivo. Results: ME1 absence in SS was confirmed in clinical samples, SS cell lines, and an SS tumor model. Investigation of SS glucose metabolism revealed that ME1-null cells exhibit higher rates of glycolysis and higher flux of glucose into the pentose phosphate pathway (PPP), which is necessary to produce NADPH. Evaluation of cellular redox homeostasis demonstrated that ME1 absence shifts dependence from the glutathione system to the thioredoxin system. Concomitantly, ME1 absence drives the accumulation of ROS and labile iron. ROS and iron accumulation enhances the susceptibility of ME1-null cells to ferroptosis induction with inhibitors of xCT (erastin and ACXT-3102). In vivo xenograft models of ME1-null SS demonstrate significantly increased tumor response to ACXT-3102 compared with ME1-expressing controls. Conclusions: These findings demonstrate the translational potential of targeting redox homeostasis in ME1-null cancers and establish the preclinical rationale for a phase I trial of ACXT-3102 in SS patients. See related commentary by Subbiah and Gan, p. 3408

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MAMark Agulnik
Mark Agulnik
NMNisha Anjali Mohindra
Nisha Anjali Mohindra
Mohammed MilhemMohammed Milhem
Mohammed Milhem
SASteven Attia
Steven Attia
Steven Ian RobinsonSteven Ian Robinson
Steven Ian Robinson
BTBrian Andrew Van Tine
Brian Andrew Van Tine
11550 Background: Topotecan and pazopanib (PAZ) individually have clinical benefit in patients (pts) with sarcomas. PAZ is a multi-tyrosine kinase inhibitor and topotecan affects endothelial cells, and inhibits HIF-1, an upstream regulator of VEGF expression. The utilization of PAZ with topotecan is anticipated to produce anti-tumor synergism in pts with sarcomas. Methods: A phase II study of PAZ/topotecan in pts with metastatic and non-resectable bone and soft tissue sarcomas (STS) was conducted by the Midwest Sarcoma Trials Partnership. Age > 18, ECOG ≤1, adequate organ function, measurable disease and 1 prior therapy were required. Pts were treated with PAZ 800mg oral daily, Topotecan 8mg orally day 1, 8, 15 on a 28-day cycle until disease progression or unacceptable toxicity. Pts enrolled in 3 cohorts: 1. STS non-liposarcoma 2. osteosarcoma 3. liposarcoma. Primary endpoint: progression-free rate (PFR) at 12 weeks in cohort 1. Secondary endpoints: overall response rate (ORR), clinical benefit rate (CBR), OS, median progression free survival (PFS), PFR at 12 weeks in cohort 2 and 3, and safety and tolerability. Lab correlates evaluated PFR and OS to levels of VEGFR2 and PDGF. Simon 2-stage design was used for cohort 1. Results: A total of 139 pts were enrolled at 6 sites, with 121 evaluable for response. Data per cohorts 1,2, and 3: # of pts- 103, 17 and 19; mean age- 56, 41, 57; % female- 63, 53, 32%; 1-2 prior therapies- 75, 65, 84%. PFR at 12 weeks is 57.5%, 62.5%, 31.3% with a median PFS of 4.4, 4.5, 1.4 months and OS of 9.8, 11.1, 12.3 months. ORR is 8,6,0 % and CBR is 74, 88, 38%. Grade 3-4 adverse events (%): neutropenia (42), thrombocytopenia (29), hypertension (16) and anemia (12). Pts in cohort 1 who progressed within 6 weeks received 61% of prescribed PAZ dose vs. 67% for those with did not progress. Histologies in cohort 1- LMS (49%), UPS (15%), synovial (10%). Correlative data will be presented. Conclusions: The combination of PAZ/topotecan produced identical results to historical data for PAZ alone in pts with STS, except with a worse toxicity profile. For pts with osteosarcoma, the combination proved extremely promising and cohort 2 will be expanded. The combination was ineffective in liposarcoma. Clinical trial information: NCT02357810.


31 March 2023
Verified
Other
Open access
CBCaitlyn B. Brashears
Caitlyn B. Brashears
BPBethany C. Prudner
Bethany C. Prudner
RRRicha Rathore
Richa Rathore
KCKatharine E. Caldwell
Katharine E. Caldwell
CDCarina A. Dehner
Carina A. Dehner
Brian Van TineBrian Van Tine
Brian Van Tine
Supplementary Figure from Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102